| Item Type | Name |
|
Concept
|
Antigen Presentation
|
|
Concept
|
Receptors, Antigen, T-Cell, alpha-beta
|
|
Concept
|
Ki-67 Antigen
|
|
Concept
|
Receptors, Antigen, T-Cell
|
|
Concept
|
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor
|
|
Concept
|
Lewis X Antigen
|
|
Concept
|
HLA-A2 Antigen
|
|
Academic Article
|
Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy.
|
|
Academic Article
|
Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions.
|
|
Academic Article
|
Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.
|
|
Academic Article
|
A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.
|
|
Academic Article
|
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.
|
|
Academic Article
|
Targeting the MAGE A3 antigen in pancreatic cancer.
|
|
Academic Article
|
Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells.
|
|
Academic Article
|
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.
|
|
Academic Article
|
The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
|
|
Academic Article
|
Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.
|
|
Academic Article
|
Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression.
|
|
Academic Article
|
A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression.
|
|
Academic Article
|
Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.
|
|
Academic Article
|
Cancer immunotherapy highlights from the 2014 ASCO Meeting.
|
|
Academic Article
|
Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.
|
|
Academic Article
|
Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy.
|
|
Academic Article
|
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.
|
|
Academic Article
|
Targeted Therapies Combined With Immune Checkpoint Therapy.
|
|
Academic Article
|
Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice
|
|
Academic Article
|
Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice.
|
|
Academic Article
|
Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors.
|
|
Academic Article
|
Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma.
|
|
Academic Article
|
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
|
|
Academic Article
|
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
|
|
Academic Article
|
Loss of IFN-? Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.
|
|
Academic Article
|
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.
|
|
Academic Article
|
Interaction of molecular alterations with immune response in melanoma.
|
|
Academic Article
|
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.
|
|
Academic Article
|
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.
|
|
Academic Article
|
Hallmarks of response to immune checkpoint blockade.
|
|
Academic Article
|
Immunotherapy resistance: the answers lie ahead - not in front - of us.
|
|
Academic Article
|
TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence.
|
|
Academic Article
|
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
|
|
Academic Article
|
RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma.
|
|
Academic Article
|
Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.
|
|
Academic Article
|
The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies.
|
|
Academic Article
|
The gut microbiota influences anticancer immunosurveillance and general health.
|
|
Academic Article
|
Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma.
|
|
Academic Article
|
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers.
|
|
Academic Article
|
Combination Immunotherapy Development in Melanoma.
|
|
Academic Article
|
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.
|
|
Academic Article
|
B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density.
|
|
Academic Article
|
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer.
|
|
Concept
|
gp100 Melanoma Antigen
|
|
Concept
|
MART-1 Antigen
|
|
Concept
|
B7 Antigens
|
|
Concept
|
B7-H1 Antigen
|
|
Concept
|
CTLA-4 Antigen
|
|
Academic Article
|
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Response.
|
|
Academic Article
|
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade.
|
|
Academic Article
|
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
|
|
Academic Article
|
Immune and Circulating Tumor DNA Profiling After Radiation Treatment for Oligometastatic Non-Small Cell Lung Cancer: Translational Correlatives from a Mature Randomized Phase II Trial.
|
|
Academic Article
|
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.
|
|
Academic Article
|
Tertiary lymphoid structures improve immunotherapy and survival in melanoma.
|
|
Academic Article
|
T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma.
|
|
Academic Article
|
Anti-tumour immunity induces aberrant peptide presentation in melanoma.
|
|
Academic Article
|
Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation.
|
|
Academic Article
|
Identification of bacteria-derived HLA-bound peptides in melanoma.
|
|
Academic Article
|
Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1.
|
|
Academic Article
|
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.
|
|
Academic Article
|
Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer.
|
|
Academic Article
|
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy.
|
|
Academic Article
|
Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1).
|
|
Academic Article
|
Androgen drives melanoma invasiveness and metastatic spread by inducing tumorigenic fucosylation.
|